Alternatives to Hexagon

Industrial AI software company providing data management and contextualization platforms for heavy-asset industries.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Integrated drug development solutions for pharmaceutical and biotechnology companies, from preclinical to clinical trials.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Global life sciences company providing diagnostic and biopharma laboratory services.

Leveraging the adaptive immune system to diagnose and treat disease.

Physics-based software platform for molecular discovery and design in life and materials sciences.

Cradle Bio B.V. is a Dutch, Swiss biotechnology company that develops software using machine learning for protein engineering. It was founded in 2021 and is base

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

AI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.

Develops a computational model of the human body for drug discovery and development.

Global contract research, development, and manufacturing organization for pharmaceutical and biopharmaceutical industries.

R&D cloud platform for life sciences, enabling scientific innovation and productivity.

Global CRDMO providing integrated R&D and manufacturing services for the pharmaceutical and life sciences industries.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

A global oncology company developing and commercializing innovative cancer treatments.

AI-powered platform for understanding disease biology and accelerating drug discovery.

AI-driven drug discovery platform accelerating breakthrough scientific research.

AI-powered spatial biology platform for precision medicine and drug development.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

AI-driven digital twin of embryo development for cell-based therapies.

AI-guided drug discovery platform for tissue-targeted medicines.

Phenomics-driven AI company translating disease biology into precision medicine discoveries.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.

Developing engineered biologics to harness the immune system for disease treatment.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

AI-powered platform for designing novel molecular structures for new medicines.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

AI-powered research assistant for scientific literature review and data extraction.

Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science.

Remote-controlled micro-robots for precise treatment of central nervous system disorders.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Lunit is a medical AI company developing AI-powered solutions for cancer diagnostics and therapeutics.

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.

Mapping cell-cell communication at scale in human tissue.

Computational protein design company creating novel enzymes and proteins using AI and physics-based modeling.

Global supplier of life science research tools, including antibodies, reagents, and assays.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

Leveraging quantum mechanics for accelerated molecular simulations in drug discovery.

AI-powered biotechnology company developing RNA therapeutics for genetic diseases.

AI-driven drug discovery company developing novel medicines for unmet patient needs.

AI-driven drug discovery platform for rapid development of novel therapeutics.

Pasqal develops quantum computing solutions for complex scientific and industrial problems.

A vertically-integrated procurement platform for the life sciences industry.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Atomwise uses AI to accelerate the discovery of novel small molecule therapeutics with its AtomNet platform.

Quantum software company enabling breakthroughs in chemistry, materials science, and life sciences.

ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

AI-powered drug discovery platform using foundation models for molecular design.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

AI-powered platform for predicting drug efficacy and safety, reducing clinical trial failures.